Highmark Inc. violated a contract with UPMC over payments for chemotherapy, an arbitration panel has ruled, meaning the health insurer must now pay millions of dollars for past claims by its members for cancer care.
The panel specifically awarded UPMC Presbyterian Shadyside Hospital $24 million for treating Highmark members with cancer since April 2014, but both sides have agreed to determine the total amount owed to all UPMC hospitals. In a regulatory filing Tuesday, UPMC said the total could top $188 million.
“The panel has unanimously concluded that Highmark was not entitled to make unlimited unilateral adjustments to its fee schedule,” the arbitrators wrote in the panel’s decision. “To now argue, as Highmark does, that it had the right to unilaterally invalidate the agreed-upon commercial hospital rate increases is completely lacking in credibility or evidentiary foundation.”
Negotiations over cancer therapy rates began in 2010 as part of an overall agreement between the two Pittsburgh health care titans. The negotiations collapsed a year later with Highmark’s decision to buy the West Penn Allegheny Health System. Court battles ensued, including a case that UPMC appealed to the state Supreme Court in which the health care provider had decided to drop Highmark’s Medicare Advantage members. A decision in that matter is pending.
The ruling in the payments for cancer care promises higher rates for people with group health insurance through Highmark, the region’s dominant carrier, insurance brokers say, because higher costs of care will eventually be passed along to members.
But companies that are self-insured through Highmark for health care expenses, including banking giant PNC and U.S. Steel, could see higher costs much sooner as a result of the decision, plus surcharges for past cancer care provided to employees at UPMC hospitals.
Read More
“Anything that adds to higher costs translates into higher rates,” said ARMS Insurance Group Vice President Dave Scott. “It’s disappointing.”
Self-insured companies make up more than half of Highmark’s health insurance business. The insurer has cautioned companies about possible surcharges for past care in the event of an unfavorable ruling, according to a broker who was familiar with the updates.
That means past claims that have already been paid for cancer care will have to be reprocessed, with employers billed the difference.
UPMC officials declined to comment on the ruling.
Highmark spokesman Aaron Billger said the insurer’s efforts have resulted in lower rates for cancer drugs than if the company had not challenged UPMC with a lawsuit last year.
“In 2014, Highmark took a stand to end UPMC’s irrational oncology drug pricing, which we estimate cost the community more than $100 million annually,” Mr. Billger wrote. “These were not funds that Highmark paid, but rather that employers and self-insured customers paid.”






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.